IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Immunome statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Immunome | Industry median |
|---|---|---|
| Market Cap | $1.90B | $166.30M |
| Enterprise Value | $1.32B | $88.19M |
| PS Ratio | 474.39 | 3.65 |
| PB Ratio | 3.24 | 2.03 |
| P/TBV Ratio | 3.24 | 2.29 |
Enterprise value
| Measure | Immunome | Industry median |
|---|---|---|
| EV / Sales | 329.27 | 2.51 |
Income (trailing twelve months)
| Measure | Immunome | Industry median |
|---|---|---|
| Revenue | $4.02M | $58.34M |
| Operating Income | -$238.81M | -$21.40M |
| Net Income | -$224.59M | -$22.46M |
| EBITDA | -$236.35M | -$16.91M |
| EPS (Diluted) | -$2.37 | -$0.83 |
Margins
| Measure | Immunome | Industry median |
|---|---|---|
| Operating Margin | -5947.9% | -44.0% |
| Profit Margin | -5593.8% | -40.2% |
| EBITDA Margin | -5886.7% | -30.2% |
| FCF Margin | -5118.9% | -9.27% |
Returns
| Measure | Immunome | Industry median |
|---|---|---|
| Return on Equity (ROE) | -50.1% | -53.2% |
| Return on Assets (ROA) | -46.7% | -40.9% |
| Return on Capital Employed (ROCE) | -40.3% | -38.1% |
Growth
| Measure | Immunome | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -63.3% | 5.96% |
Balance sheet
| Measure | Immunome | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $582.69M | $61.43M |
| Net Cash (Debt) | $582.69M | $15.35M |
| Net Cash Per Share | $5.13 | $0.66 |
| Equity (Book Value) | $588.69M | $49.09M |
| Book Value Per Share | $5.18 | $1.37 |
| Tangible Book Value | $588.69M | $23.52M |
| Working Capital | $566.90M | $76.81M |
Financial position
| Measure | Immunome | Industry median |
|---|---|---|
| Current Ratio | 21.68 | 3.34 |
| Quick Ratio | 21.26 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Immunome | Industry median |
|---|---|---|
| Operating Cash Flow | -$196.50M | -$12.35M |
| Capital Expenditures | -$9.02M | -$1.08M |
| Free Cash Flow | -$205.52M | -$20.22M |
| FCF Per Share | -$1.81 | -$0.42 |
Efficiency
| Measure | Immunome | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $22.68K | $404.87K |
| Profits Per Employee | -$1.27M | -$703.34K |
| Employee Count | 177 | 74 |
Dividends and yields
| Measure | Immunome | Industry median |
|---|---|---|
| Earnings Yield | -11.8% | -23.3% |
| FCF Yield | -10.8% | -8.72% |
Shares
| Measure | Immunome | Industry median |
|---|---|---|
| Shares Outstanding | 113,578,000 | 58,127,000 |
| Shares Change (YoY) | 46.0% | 10.9% |
| Shares Change (QoQ) | 0.03% | 0.54% |
| Float | 106,256,000 | 49,136,700 |
| Shares Held by Insiders | 6.45% | 11.6% |
| Shares Held by Institutions | 103.9% | 59.4% |
Scores
| Measure | Immunome | Industry median |
|---|---|---|
| Altman Z-Score | 34.81 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Immunome's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.